Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that in collaboration with the American Society of Clinical Oncology (ASCO), the academic research community now has access to a dataset of 500 Glioblastoma patients with matched molecular and clinically data. Clinical data paired with rich DNA and RNA sequencing data for such a large cohort of Glioblastoma patients is truly unique, and investigators are now able to apply for access to this high-quality dataset for research projects.
Tempus is committed to furthering cancer research, leveraging its vast library of clinical and molecular data to propel therapeutic discovery. Tempus licensed the de-identified patient cohort to ASCO to advance current Glioblastoma research projects that can benefit from this data. The cohort is housed within ASCO’s Data Library, which aims to facilitate access by researchers to ASCO data assets.
“Now more than ever, cancer research is facing significant hurdles caused by COVID-19, including sparse funding,” said Kim Blackwell, MD, Chief Medical Officer of Tempus. “A matched dataset of this size is an invaluable tool for any study, and we hope that offering it will accelerate researchers’ work during a very critical time.”
“The availability of clinical data paired with DNA and RNA sequencing for such a large cohort of glioblastoma patients is a rare yet critical resource for studying the biology of this difficult to treat tumor and finding better prognostic and predictive biomarkers and improved treatments,” said Richard L. Schilsky, MD, FASCO, Executive Vice President and Chief Medical Officer of ASCO. “We are pleased that this collaboration will make this unique data set available to the academic research community.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.